Subcutaneous Daratumumab Monotherapy for Patients with High-Risk Smoldering Multiple Myeloma By Ogkologos - December 18, 2024 893 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AQUILA study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR Keto Molecule Offers Clue for Preventing Colorectal Cancer June 2, 2022 FDA Approves Elacestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast... February 7, 2023 ESMO Immuno-Oncology Congress 2022, 7-9 December, Geneva, Switzerland November 29, 2022 Brothers Break Down After Seeing Their Parents For First Time In... October 31, 2021 Load more HOT NEWS Osimertinib Shows Promising Activity in Previously Untreated Patients with Metastatic NSCLC... A new approach to cancer immunotherapy Treatment for Children with Leukemia Also Effective for Adolescents, Young Adults To Improve Immunotherapy, Researchers Look at Limiting Cancer’s Access to Sugar...
